2021
Meta-Analysis: Pediatric Placebo Response in Depression Trials Does Not Replicate in Anxiety and Obsessive-Compulsive Disorder Trials
Nasir M, Li F, Courley S, Olten B, Bloch MH. Meta-Analysis: Pediatric Placebo Response in Depression Trials Does Not Replicate in Anxiety and Obsessive-Compulsive Disorder Trials. Journal Of Child And Adolescent Psychopharmacology 2021, 31: 670-684. PMID: 34558984, DOI: 10.1089/cap.2021.0030.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnxietyAnxiety DisordersChildDepressionHumansObsessive-Compulsive DisorderPlacebo EffectConceptsPlacebo response ratesObsessive-compulsive disorderPlacebo responseDepression trialsResponse ratePlacebo improvementSymptom improvementAntidepressant trialsStratified subgroup analysisRandom-effects modelPediatric populationSubgroup analysisStudy visitNumber of subjectsPsychopharmacological trialsPubMed searchDifferent indicationsDiagnostic indicationsMean differenceAnxiety disordersTrialsDisordersPediatric anxietyPredictorsPossible correlates
2020
Systematic review and meta-analysis: effects of maternal separation on anxiety-like behavior in rodents
Wang D, Levine JLS, Avila-Quintero V, Bloch M, Kaffman A. Systematic review and meta-analysis: effects of maternal separation on anxiety-like behavior in rodents. Translational Psychiatry 2020, 10: 174. PMID: 32483128, PMCID: PMC7264128, DOI: 10.1038/s41398-020-0856-0.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnxietyAnxiety DisordersBehavior, AnimalExploratory BehaviorMaternal DeprivationMiceRatsRodentiaConceptsOpen field testEarly life stressSystematic reviewEffects of MSEffects of ELSAnxiety-like behaviorDefensive behaviorAnxiogenic effectsMaternal separationRodent modelsRatsEarly adversityMiceAbility of MSLife stressLack of standardizationChildhood maltreatmentRodentsExploratory behaviorEffect sizeInconsistent resultsELS modelImportant differencesReviewMS protocol
2019
Efficacy and Tolerability of Pharmacotherapy for Pediatric Anxiety Disorders: A Network Meta-Analysis.
Dobson ET, Bloch MH, Strawn JR. Efficacy and Tolerability of Pharmacotherapy for Pediatric Anxiety Disorders: A Network Meta-Analysis. The Journal Of Clinical Psychiatry 2019, 80 PMID: 30753760, DOI: 10.4088/jcp.17r12064.Peer-Reviewed Original ResearchMeSH KeywordsAnxiety DisordersChildHumansNetwork Meta-AnalysisNeurotransmitter Uptake InhibitorsTreatment OutcomeConceptsSerotonin-norepinephrine reuptake inhibitorsSelective serotonin reuptake inhibitorsTolerability of pharmacotherapyTreatment-emergent suicidalityMedication classesTreatment responsePediatric anxiety disordersAnxiety disordersReuptake inhibitorsTolerability of medicationsPlacebo-controlled trialSerotonin reuptake inhibitorsNetwork Meta-AnalysisRisk of biasWeb of ScienceCause discontinuationGeMTC packageSuicidality dataCochrane riskMultiple medicationsBias toolPediatric patientsMedication trialsAgonist treatmentCochrane Database
2018
Systematic review and meta‐analysis: Dose–response curve of SSRIs and SNRIs in anxiety disorders
Jakubovski E, Johnson JA, Nasir M, Müller‐Vahl K, Bloch MH. Systematic review and meta‐analysis: Dose–response curve of SSRIs and SNRIs in anxiety disorders. Depression And Anxiety 2018, 36: 198-212. PMID: 30479005, DOI: 10.1002/da.22854.Peer-Reviewed Original ResearchConceptsSerotonin-norepinephrine reuptake inhibitorsSelective serotonin reuptake inhibitorsGreater treatment benefitHigh dosesTreatment responseAnxiety disordersReuptake inhibitorsSymptom improvementTreatment benefitPharmacological agentsRandomized placebo-controlled clinical trialSSRIs/serotonin-norepinephrine reuptake inhibitorsPlacebo-controlled clinical trialIndividual pharmacological agentsCochrane Central RegisterNorepinephrine reuptake inhibitorsSerotonin reuptake inhibitorsOverall symptom improvementGreater symptom improvementDose-response curveLinear mixed model analysisCentral RegisterMedication classesAdult patientsControlled Trials
2017
Monotherapy Insufficient in Severe Anxiety? Predictors and Moderators in the Child/Adolescent Anxiety Multimodal Study
Taylor JH, Lebowitz ER, Jakubovski E, Coughlin CG, Silverman WK, Bloch MH. Monotherapy Insufficient in Severe Anxiety? Predictors and Moderators in the Child/Adolescent Anxiety Multimodal Study. Journal Of Clinical Child & Adolescent Psychology 2017, 47: 266-281. PMID: 28956620, PMCID: PMC6191182, DOI: 10.1080/15374416.2017.1371028.Peer-Reviewed Original ResearchConceptsChild/Adolescent Anxiety Multimodal StudyCognitive behavioral therapyModerators of outcomeSevere anxietyCombination of CBTIndependent evaluator ratingsMultimodal studyParent-rated anxietySeparation anxiety disorderMain effect findingsObsessive-compulsive disorderAnxious youthSocial anxietyChild anxietyBehavioral therapyAnxiety severityPill placeboAnxiety disordersEvaluators' ratingsAnxietyModeratorSocioeconomic statusLow socioeconomic statusYouthEffect findingsMeta‐analysis: Risk of hyperhidrosis with second‐generation antidepressants
Beyer C, Cappetta K, Johnson JA, Bloch MH. Meta‐analysis: Risk of hyperhidrosis with second‐generation antidepressants. Depression And Anxiety 2017, 34: 1134-1146. PMID: 28881483, DOI: 10.1002/da.22680.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive Agents, Second-GenerationAnxiety DisordersDepressive DisorderHumansHyperhidrosisObsessive-Compulsive DisorderConceptsSSRI/SNRI medicationsSerotonin-norepinephrine reuptake inhibitorsSecond-generation antidepressantsAntidepressant medicationSNRI medicationsMost antidepressant medicationsPlacebo-controlled trialPooled risk ratioStratified subgroup analysisTreatment of adultsReceptor affinity profileMedication classesReuptake inhibitorsMedication typeObsessive-compulsive disorderAntidepressant agentsRisk ratioSubgroup analysisDepressive disorderDopamine transporter affinityHyperhidrosisMedicationsPubMed searchSide effectsDopamine transporterRandomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder. The Journal Of Clinical Psychiatry 2017, 78: e766-e773. PMID: 28617566, DOI: 10.4088/jcp.16m11101.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineAdolescentAdultAgedAnxiety DisordersComorbidityDepressive DisorderDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationFemaleHumansMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychometricsSelective Serotonin Reuptake InhibitorsYoung AdultConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderY-BOCS scoresN-acetylcysteineNAC groupYale-Brown Obsessive Compulsive Scale scoresTreatment-resistant OCD patientsBaseline Y-BOCS scoresTreatment-Resistant ObsessivePrimary outcome measureAnxiety symptomsDSM-IV criteriaSymptom dimensionsCompulsive Scale scoresSpecific OCD symptom dimensionsOCD symptom dimensionsAntioxidant medicationsAbdominal painPlacebo groupGlutamate modulatorsSecondary outcomesTertiary hospitalOutpatient clinicSeverity scoreWeek 16The efficacy of benzodiazepines as acute anxiolytics in children: A meta‐analysis
Kuang H, Johnson JA, Mulqueen JM, Bloch MH. The efficacy of benzodiazepines as acute anxiolytics in children: A meta‐analysis. Depression And Anxiety 2017, 34: 888-896. PMID: 28504861, PMCID: PMC5629100, DOI: 10.1002/da.22643.Peer-Reviewed Original ResearchConceptsEfficacy of benzodiazepinesPediatric patientsAnxiety disordersTolerability of benzodiazepinesRoom proceduresCurrent practice guidelinesStandardized mean differenceFunnel plot asymmetryOperating room proceduresProcedural settingsPediatric anxiety disordersTolerability analysisAcute managementBenzodiazepine treatmentStratified subgroupsPractice guidelinesControl groupAcute anxiolyticPublication biasAnxiolyticsBenzodiazepinesMean differencePatientsSpecific agentsAnxiety levels
2015
Family accommodation in obsessive-compulsive and anxiety disorders: a five-year update
Lebowitz ER, Panza KE, Bloch MH. Family accommodation in obsessive-compulsive and anxiety disorders: a five-year update. Expert Review Of Neurotherapeutics 2015, 16: 45-53. PMID: 26613396, PMCID: PMC4895189, DOI: 10.1586/14737175.2016.1126181.Peer-Reviewed Original ResearchConceptsFamily accommodationObsessive-compulsive disorderAnxiety disordersNeurobiological underpinningsSevere psychopathologySynthesis of findingsPsychiatric disordersDisordersPsychopathologyMain findingsDistressAccommodationFindingsUnderpinningsEnglish language papersFive-Year UpdatePsycINFOTherapeutic goalsIndividualsLanguage papersResearchAnxiety Disorder-Specific Predictors of Treatment Outcome in the Coordinated Anxiety Learning and Management (CALM) Trial
Jakubovski E, Bloch MH. Anxiety Disorder-Specific Predictors of Treatment Outcome in the Coordinated Anxiety Learning and Management (CALM) Trial. Psychiatric Quarterly 2015, 87: 445-464. PMID: 26563229, DOI: 10.1007/s11126-015-9399-6.Peer-Reviewed Original ResearchConceptsSocial anxiety disorderAnxiety disordersCoordinated Anxiety LearningAnxiety LearningPost-traumatic stress disorderSelf-efficacy expectanciesPositive treatment expectanciesGeneralized anxiety disorderTreatment outcomesStress disorderTreatment expectanciesSpecific treatment needsSocial supportPanic disorderDisordersLearningSocioeconomic statusPredictors
2014
Prognostic subgroups for remission and response in the Coordinated Anxiety Learning and Management (CALM) trial.
Kelly JM, Jakubovski E, Bloch MH. Prognostic subgroups for remission and response in the Coordinated Anxiety Learning and Management (CALM) trial. The Journal Of Clinical Psychiatry 2014, 76: 267-78. PMID: 25562579, PMCID: PMC4930076, DOI: 10.4088/jcp.13m08922.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenergic Uptake InhibitorsAdultAgedAnti-Anxiety AgentsAnxiety DisordersBenzodiazepinesCognitive Behavioral TherapyCombined Modality TherapyDepressive Disorder, MajorFemaleHumansMaleMiddle AgedOutcome Assessment, Health CarePanic DisorderPhobic DisordersPrognosisRemission InductionSelective Serotonin Reuptake InhibitorsSeverity of Illness IndexSex FactorsSocial ClassSocial SupportStress Disorders, Post-TraumaticYoung AdultConceptsLow socioeconomic statusCoordinated Anxiety LearningUsual careGeneralized anxiety disorderPosttraumatic stress disorderAnxiety disordersBaseline characteristicsPatient characteristicsPrognostic subgroupsAnxiety LearningSocioeconomic statusBaseline patient characteristicsCollaborative care interventionPrimary care settingPoor treatment outcomesCommunity treatment centersDSM-IV criteriaManagement trialsCognitive behavioral therapyLimited social supportExploratory moderator analysesMost patientsRemission criteriaComorbid depressionPrognostic outcomesA meta-analysis of computerized cognitive-behavioral therapy for the treatment of DSM-5 anxiety disorders.
Adelman CB, Panza KE, Bartley CA, Bontempo A, Bloch MH. A meta-analysis of computerized cognitive-behavioral therapy for the treatment of DSM-5 anxiety disorders. The Journal Of Clinical Psychiatry 2014, 75: e695-704. PMID: 25093485, DOI: 10.4088/jcp.13r08894.Peer-Reviewed Original ResearchMeSH KeywordsAnxiety DisordersCognitive Behavioral TherapyDiagnostic and Statistical Manual of Mental DisordersHumansUser-Computer InterfaceConceptsCognitive behavioral therapyPerson cognitive-behavioural therapyComputerized cognitive behavioral therapyAnxiety disordersComputerized CBTNon-PTSD anxiety disordersCompletion of treatmentTreatment gainsStandardized mean differenceDSM-5 anxiety disordersGreater symptom reductionWait-list controlSpecific anxiety disordersFixed-effects modelClinical outcomesClinical comorbiditiesEfficacious interventionsSymptom reductionReal-world settingGreater efficacyMeta-AnalysisCBT treatmentMean differenceDisordersAnxiety symptomsPrognostic subgroups for citalopram response in the STAR*D trial.
Jakubovski E, Bloch MH. Prognostic subgroups for citalopram response in the STAR*D trial. The Journal Of Clinical Psychiatry 2014, 75: 738-47. PMID: 24912106, PMCID: PMC4471174, DOI: 10.4088/jcp.13m08727.Peer-Reviewed Original ResearchConceptsMajor depressive disorderBaseline clinical characteristicsClinical characteristicsTreatment successTreatment outcomesTreatment responseSide effectsSelective serotonin reuptake inhibitor (SSRI) pharmacotherapyEarly symptom improvementInitial clinical characteristicsOpen-label citalopramPrimary outcome measureFirst treatment phasePast treatment historySequenced Treatment AlternativesDSM-IV diagnosisTraditional psychiatric diagnosesDifferential treatment outcomesSSRI treatmentSymptom improvementMDD patientsMedication responsePoor responseDepressive disorderPrognostic subgroups
2013
Meta-analysis: Aerobic exercise for the treatment of anxiety disorders
Bartley CA, Hay M, Bloch MH. Meta-analysis: Aerobic exercise for the treatment of anxiety disorders. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2013, 45: 34-39. PMID: 23643675, DOI: 10.1016/j.pnpbp.2013.04.016.Peer-Reviewed Original ResearchAge and Gender Correlates of Pulling in Pediatric Trichotillomania
Panza KE, Pittenger C, Bloch MH. Age and Gender Correlates of Pulling in Pediatric Trichotillomania. Journal Of The American Academy Of Child & Adolescent Psychiatry 2013, 52: 241-249. PMID: 23452681, PMCID: PMC3745006, DOI: 10.1016/j.jaac.2012.12.019.Peer-Reviewed Original ResearchConceptsFrequent urgesCommon comorbid conditionsPediatric trichotillomaniaProspective longitudinal studyType of treatmentCross-sectional findingsClinical characteristicsComorbid conditionsStructured rating scaleTreatment trialsComorbid depressionRating ScaleAnxiety disordersOlder childrenTrichotillomaniaDecreased abilityLongitudinal studyMale participantsAgeChildrenGreater distressFemale participantsLower ratesSymptomsGender correlates
2012
D-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: a meta-analysis.
Bontempo A, Panza KE, Bloch MH. D-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: a meta-analysis. The Journal Of Clinical Psychiatry 2012, 73: 533-7. PMID: 22579153, PMCID: PMC3625928, DOI: 10.4088/jcp.11r07356.Peer-Reviewed Original Research
2008
Riluzole in the Treatment of Mood and Anxiety Disorders
Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G. Riluzole in the Treatment of Mood and Anxiety Disorders. CNS Drugs 2008, 22: 761-786. PMID: 18698875, DOI: 10.2165/00023210-200822090-00004.Peer-Reviewed Original ResearchConceptsTreatment of moodAnxiety disordersMultiple molecular actionsOpen-label trialPlacebo-controlled trialAmino acid neurotransmissionCommon adverse effectsLiver function testsAmyotrophic lateral sclerosisVoltage-gated sodium channelsBorderline personality disorderSelf-injurious behaviorStandard therapyIll patientsBipolar depressionFunction testsObsessive-compulsive disorderCase reportGlutamatergic neurotransmissionGlutamate levelsExtracellular glutamateClinical consequencesLateral sclerosisAstrocytic uptakeRiluzole